Jefferies Lifts PT on Lantheus Holdings (LNTH) to $110 From $105 – Here’s Why

Group 1 - Lantheus Holdings, Inc. (NASDAQ:LNTH) is recognized as a high growth healthcare stock, with Jefferies raising its price target from $105 to $110 and maintaining a Buy rating [1] - Jefferies updated its PSMA PET model, projecting market volume growth of approximately 20% in 2025 and 10%-11% in 2026, with the commercial rollout of PYLARIFY TruVu expected in Q4 2026 [1] - The FDA has extended the review of Lantheus's New Drug Application for LNTH-2501 by three months to June 29, 2026, with the extension not related to efficacy or safety data [2] Group 2 - Lantheus Holdings, Inc. specializes in diagnostic imaging and nuclear medicine products, aiding healthcare professionals in patient management and cardiovascular disease detection [3] - The company's operations are segmented into U.S. and International markets, indicating a diversified geographical presence [3]